- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01744860
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
25 февраля 2016 г. обновлено: Hoffmann-La Roche
Evaluation of Concordance Between the Methods Used in INCa Platforms and the Cobas® 4800 BRAF V600 Mutation Test for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting
This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples.
No patients will be enrolled in this study.
Data will be collected for approximately 6 months.
Обзор исследования
Статус
Завершенный
Условия
Тип исследования
Наблюдательный
Регистрация (Действительный)
420
Контакты и местонахождение
В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.
Места учебы
-
-
-
Boulogne Billancourt, Франция, 92104
-
Colmar, Франция, 68024
-
Lille, Франция, 59037
-
Lyon, Франция, 69437
-
Marseille, Франция, 13015
-
Montpellier, Франция, 34295
-
Nantes, Франция, 44093
-
Paris, Франция, 75010
-
Pessac, Франция, 33604
-
Rouen, Франция, 76031
-
Vandoeuvre Les Nancy, Франция, 54511
-
Villejuif, Франция, 94505
-
-
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Нет
Полы, имеющие право на обучение
Все
Метод выборки
Вероятностная выборка
Исследуемая популяция
No patients are enrolled in this study.
Use of melanoma tumor samples.
Описание
Inclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Histologically proven melanoma tumor sample
- Any type of tumor sample: biopsy or surgical specimen of primary tumor or metastasis
- Tumor samples must be fixed and paraffin-embedded.
Exclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Fixative unknown
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
|---|
|
INCa molecular genetics laboratory "in-house" methods
BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods
|
|
Cobas 4800 Mutation Test
BRAF V600 mutations were analysed using Cobas 4800 mutation test
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories
Временное ограничение: Up to 6 months
|
BRAF V600 mutation status was determined by INCa molecular laboratories "in-house" methods and Cobas 4800 BRAF V600 mutation test.
Samples were analysed as V600 mutation, No V600 mutation and Non evaluable.
Additionally, the type of V600 mutation (E, K, R, D, E2, other V600 mutation, not specified) was also evaluated only by INCa molecular laboratory "in-house" method.
|
Up to 6 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Tumor Sample Characteristics-Type of Tumor Sample
Временное ограничение: Up to 6 months
|
The type of tumor sample used for evaluation of BRAF V600 mutation whether it was a biopsy or surgical specimen were reported
|
Up to 6 months
|
|
Tumor Sample Characteristics - Source of Tumor Sample
Временное ограничение: Up to 6 months
|
The source of tumor sample for BRAF V600 mutation detection whether taken from internal or external pathology laboratory were reported
|
Up to 6 months
|
|
Type of Pathology Laboratory Performing the Fixation or Embedding-Pre-analytical Method
Временное ограничение: Up to 6 months
|
The external or internal pathology laboratories involved in the process of fixation or embedding of the tumor sample was evaluated.
|
Up to 6 months
|
|
Time From Sampling to Fixation- Pre-analytical Method
Временное ограничение: Up to 6 months
|
Time taken from the sampling to the fixation of the tumor sample was reported in range of 0-2 hours, 2-6 hours, >6 hours and unknown.
Number of samples falling in each of the class were reported.
|
Up to 6 months
|
|
Type of Fixative Used- Pre-analytical Method
Временное ограничение: Up to 6 months
|
The different types of fixative Excell, formol, alcohol formol acetic acid and other, used to fix the tumor samples were reported.
|
Up to 6 months
|
|
Fixation Duration by Pre-analytical Method
Временное ограничение: Up to 6 months
|
Fixation duration is defined as the amount of time required in hours for the fixation of a samples.
The fixation duration was categorized as <6 hours, 6-24 hours and >24 hours and unknown.
Number of samples falling in each category were reported
|
Up to 6 months
|
|
Slice Thickness by Pre-analytical Method
Временное ограничение: Up to 6 months
|
Slice thickness of all the tumour samples was measured.
The slice thickness was measured in micrometer.
|
Up to 6 months
|
|
Dewaxing by Pre-analytical Method
Временное ограничение: Up to 6 Months
|
Dewaxing is a method to recover the DNA from samples.
Dewaxing information was collected as "Yes, No or Missing"
|
Up to 6 Months
|
|
Necrosis Percentage Determination by Pre-analytical Method
Временное ограничение: Up to 6 months
|
The percentage of necrosis defined as the death of one or more cells in the analysed zone was reported.
|
Up to 6 months
|
|
Percentage of Tumor Cells by Pre-analytical Method
Временное ограничение: Up to 6 months
|
The percentage of tumor cells in the given tumor sample were reported.
|
Up to 6 months
|
|
Tumor Samples With Presence of Melanin by Pre-analytical Method
Временное ограничение: Up to 6 months
|
The tumor samples with presence of melanin were categorized as Important, Few, Medium and Absent.
|
Up to 6 months
|
|
DNA Extraction - Extraction Method by Pre-analytical Method
Временное ограничение: Up to 6 months
|
This method assessed DNA from the tumor samples was extracted by Automated method or Manual method.
|
Up to 6 months
|
|
Median DNA Elution Volume by Pre-analytical Method
Временное ограничение: Up to 6 months
|
Median DNA elution volume microliters [mcl] was reported.
|
Up to 6 months
|
|
Mean DNA Concentration by Pre-analytical Method
Временное ограничение: Up to 6 months
|
The DNA concentration in the tissue elute was measured in nanogram per microliter (ng/mcL).
|
Up to 6 months
|
|
Amount of DNA by Pre-analytical Method
Временное ограничение: Up to 6 months
|
The total DNA concentration extracted from the tissue was measured in nanogram (ng).
|
Up to 6 months
|
|
Size of Amplicons Used by "In-house" Analytical Method
Временное ограничение: Up to 6 months
|
The method described the size of amplicon used.
It was measured in base pairs (bp).
|
Up to 6 months
|
|
Method of Mutation Detection by "In-house" Analytical Method
Временное ограничение: Up to 6 months
|
Allele-specific PCR, High Resolution Melting (HRM) + Sanger sequencing, Pyrosequencing, Sanger sequencing, Real time PCR, SNaPshot were used for BRAF V600 mutation detection.
|
Up to 6 months
|
|
Number of Samples Punched in In-house Analytical Method
Временное ограничение: Up to 6 months
|
Total number of samples for whom punch was used in 'in-house analytical' method are reported.
|
Up to 6 months
|
|
Mean Number of Slices Per Sample Used for "In-house"- Analytical Method
Временное ограничение: Up to 6 months
|
The mean of number of slices per sample when no punch was used are reported.
|
Up to 6 months
|
|
Median Time Between Receipt of Samples and Determination of Result by "In-house" Analytical Method
Временное ограничение: Up to 6 months
|
This In-house analytical method measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by "In-house" Analytical Method
Временное ограничение: Up to 6 months
|
The working time required by the technician from the time of DNA extraction to the time to obtain the results was measured in hours.
|
Up to 6 months
|
|
Mean DNA Concentration as Measured by COBAS 4800 BRAF V600 Mutation Test-Analytical Method
Временное ограничение: Up to 6 months
|
The DNA concentration as assessed by COBAS 4800 BRAF V600 Mutation assay was reported.
The unit used to measure the DNA concentration was nanogram/microlitre (ng/mcl)
|
Up to 6 months
|
|
Punch Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Временное ограничение: Up to 6 months
|
The punch done during Cobas 4800 BRAF V600 Mutation Test on the sample was described as Yes or No.
|
Up to 6 months
|
|
Number of Slices Used When No Punch Was Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Временное ограничение: Up to 6 months
|
This describes the Cobas 4800 BRAF V600 Mutation Test, for the mean of number of slices when No punch method, was used.
Of the 420 samples, punch was Yes, for 45 samples and punch was No, for 375 samples.
|
Up to 6 months
|
|
Median Time Between Receipt of Sample and Determination of Result by Cobas 4800 BRAF V600 Mutation Test -Analytical Method
Временное ограничение: Up to 6 months
|
This analytical method for cobas 4800 BRAF V600 Mutation Test measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by Cobas 4800 BRAF V600 Mutation Test - Analytical Method
Временное ограничение: Up to 6 months
|
This cobas 4800 BRAF V600 Mutation Test analytical method measures the working time required by the technician from the time of DNA extraction to the time to obtain the results.
The time duration was measured in hours.
|
Up to 6 months
|
|
Management of Discordance- Method Used to Manage Discordance
Временное ограничение: Up to 6 months
|
Crossing DNA, DNA from In-House method analysed with cobas, SNaPshot, DNA from cobas analysed with In-House method, external site control test, Sanger sequencing, Kit CE-IVD Therascreen RGQ Qiagen, Kit Therascreen RGQ BRAF + Pyrosequencing by another platform (PF), Pyrosequencing, Mutation detection On Another Block, (primitive tumor [prm.
tmr]), Sequencing And Therascreen kit (Qiagen) were used for management of discordance between "in-house" method and Cobas 4800 mutation test.
|
Up to 6 months
|
|
Management of Discordance-Final Result for BRAF V600 Mutation Detection
Временное ограничение: Up to 6 months
|
The final results obtained by discordance management of the 28 discordant samples were BRAF V600 mutation, No BRAF V600 mutation and Non-evaluable.
These results were further assessed by the Investigator and interpreted as final result.
|
Up to 6 months
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Спонсор
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования
1 декабря 2012 г.
Первичное завершение (Действительный)
1 апреля 2013 г.
Завершение исследования (Действительный)
1 апреля 2013 г.
Даты регистрации исследования
Первый отправленный
6 декабря 2012 г.
Впервые представлено, что соответствует критериям контроля качества
6 декабря 2012 г.
Первый опубликованный (Оценивать)
7 декабря 2012 г.
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
28 марта 2016 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
25 февраля 2016 г.
Последняя проверка
1 ноября 2015 г.
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- ML28471
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .